Can keytruda stop smoldering myeloma in its tracks?
NCT ID NCT02603887
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing the immunotherapy drug pembrolizumab (Keytruda) in 20 people with smoldering multiple myeloma at intermediate or high risk of progression. The goal is to see if the drug can shrink the cancer or delay it from becoming active multiple myeloma. Researchers are measuring response rates and how many participants progress after eight cycles of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab (Keytruda)
What this could lead to
If it works, this could point toward a way to delay or prevent smoldering myeloma from turning into active multiple myeloma.
What could go wrong
This is a very early, small pilot study with only 20 participants, so results may not apply widely. Pembrolizumab can also cause immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMOLDERING PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States